Evidence map›Paper›PMID 38078757›Full record

ArticlemSystems2024

High-level nitrofurantoin resistance in a clinical isolate of

Maytham Hussein, Zetao Sun, Jane Hawkey, Rafah Allobawi, Louise M Judd, Vincenzo Carbone, Rajnikant Sharma, Varsha Thombare, Mark Baker, Gauri G Rao and 3 more

Open access · goldAbstract read
In one paragraph

Article in mSystems, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Tripartite Loops Reverse Antibiotic Resistance.Molecular biology and evolution · 2025
    Article
  5. CombatingFrontiers in cellular and infection microbiology · 2025
    Review
  6. Unlocking Nitrofurantoin: Understanding Molecular Mechanisms of Action and Resistance in Enterobacterales.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2025
    Review
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 4 countries.

Maytham HusseinDepartment of Pharmacology, Monash Biomedicine Discovery Institute,Monash University, Clayton, Victoria, Australia.ORCID 0000-0001-5922-7312
Zetao SunDepartment of Biochemistry and Pharmacology, School of Biomedical Sciences, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, Victoria, Australia.
Jane HawkeyDepartment of Infectious Diseases, Central Clinical School, Monash University, Melbourne, Victoria, Australia.
Rafah AllobawiDepartment of Pharmacology, Monash Biomedicine Discovery Institute,Monash University, Clayton, Victoria, Australia.
Louise M JuddDoherty Applied Microbial Genomics (DAMG), 12 Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australia.ORCID 0000-0003-3613-4839
Vincenzo CarboneAgResearch Limited, Grasslands Research Center, Tennent Drive, Palmerston North, New Zealand.
Rajnikant SharmaDivision of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, USA.
Varsha ThombareDepartment of Pharmacology, Monash Biomedicine Discovery Institute,Monash University, Clayton, Victoria, Australia.
Mark BakerDiscipline of Biological 17 Sciences, Priority Research Center in Reproductive Biology, Faculty of Science and IT, University of Newcastle, University Drive, Callaghan, New South Wales, Australia.
Gauri G RaoDivision of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, USA.ORCID 0000-0002-8704-7770
Jian LiDepartment of Pharmacology, Monash Biomedicine Discovery Institute,Monash University, Clayton, Victoria, Australia.ORCID 0000-0001-7953-8230
Kathryn E HoltDepartment of Infectious Diseases, Central Clinical School, Monash University, Melbourne, Victoria, Australia.ORCID 0000-0003-3949-2471
Tony VelkovDepartment of Pharmacology, Monash Biomedicine Discovery Institute,Monash University, Clayton, Victoria, Australia.ORCID 0000-0002-0017-7952
Australian Regenerative Medicine Institute · AUThe University of Melbourne · AUUniversity of North Carolina at Chapel Hill · USAgResearch · NZLondon School of Hygiene & Tropical Medicine · GBMonash University · AUUniversity of Newcastle Australia · AU

Funding

Pharmacology of intrathecal/intraventricular polymyxins: A systems-based approachR01AI146241 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI RAO, GAURI G, VELKOV, TONY · 2019 to 2023
$3.0M
NIAID NIH HHS R01 AI146241
6 · The paper itself

Abstract

Nitrofurantoin is a commonly used chemotherapeutic agent in the treatment of uncomplicated urinary tract infections caused by the problematic multidrug resistant Gram-negative pathogen

Indexed as

Klebsiella InfectionsUrinary Tract InfectionsAnti-Bacterial AgentsDrug Resistance, Multiple, BacterialGenomicsHumansKlebsiella pneumoniaeNitrofurantoinNitroreductasesRiboflavinRNA, TransferAnti-Bacterial AgentsNitrofurantoinNitroreductasesRiboflavinRNA, Transferantimicrobial resistancegenomicsKlebsiella pneumoniaemetabolomicsnitrofurantoin

Identifiers

PMID38078757
PMCPMC10805014
OpenAlexW4389558828

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.